Indoco’s International Business is spread across geographies, including United States of America, Europe, Australia, New Zealand and Emerging Markets. With world class R&D centre, CRO and manufacturing facilities, Indoco is the most preferred partner by the generic companies across the globe. Our strategy to focus on the niche segments of ophthalmics and injectables for US market, filing of dossiers in Own name in EU and brand building in Emerging markets will help us to achieve a sustainable growth.

International Business will continue to remain a thrust area and is slated to contribute to more than 50% of Indoco’s total revenues in future.

We have a comprehensive bucket of products, including ANDAs, EU Dossiers and a number of product registration files for Emerging Markets.